Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel aims to stop uterine scarring after surgery

NCT ID NCT07160764

Prevention Sponsor: Semikal Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether a gel called Hyalosem can prevent scar tissue from forming inside the uterus after surgery. Researchers will review the medical records of 80 women who had uterine surgery and then received the gel. The goal is to see if the gel reduces adhesions and improves menstrual health without causing harm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cross-linked hyaluronic acid gel (Hyalosem)
What this could lead to
If it works, this gel could help prevent painful scar tissue in the uterus after surgery, improving fertility and menstrual health.
What could go wrong
This is a small, retrospective study, so results may not apply to everyone. The gel might not prevent adhesions or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Female patients ages 18 years and over who are at risk of postoperative adhesion formation after operative hysteroscopy

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 and over * Patients who were treated with operative hysteroscopy for intrauterine pathology (endometrial polips, myomas with uterine cavity deformation, uterine septa, intrauterine adhesion, ovarian cyst, endometrial cyst, etc.) * Patients who had undergone operative hysteroscopy at least 30 days and at most 6 months ago * Patients who had second-look office hysteroscopy at least once after an operative hysteroscopy Exclusion Criteria: * Children and adolescents under 18 years of age * Having a body weight of more than 100 kg * Surgeries complicated by excessive bleeding; estimated blood loss of more than 100 cc * Surgeries complicated with uterine perforation * Presence of uncontrolled diabetes, coagulation disorders, and other severe chronic disorders * Presence of malignant tumor or diagnosis of cancer, presence of uterovaginal prolapse * Concomitant peritoneal grafting or tubal implantation * Concomitant intrauterine device implantation * Patients without second-look hysteroscopy According to the GDPR and clinical investigation legislation, written informed consent is not mandatory in retrospective studies as long as the patient's personal information is censored.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asherman syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adhesions of uterus Asherman syndrome endometrial polyp gynatresia ovarian cyst ovarian endometriosis septate uterus submucous uterine fibroid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asherman syndrome Asherman'S syndrome Intra-uterine adhesions Intrauterine abnormalities in infertility Postoperative adhesion of uterus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Antalya Training and Research Hospital Gynecology and Obstetrics Clinic

    Antalya, 07100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.